Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,092 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Nishiyama N, Kita Y, Ito K, Kato M, Hatakeyama S, Matsushita Y, Naito S, Miyake M, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Nishiyama H, Kobayashi T, Kitamura H; Japan Urological Oncology Group. Nishiyama N, et al. Among authors: nishiyama h. Anticancer Res. 2023 Nov;43(11):5041-5050. doi: 10.21873/anticanres.16703. Anticancer Res. 2023. PMID: 37909969
C-reactive protein as a prognostic predictor for non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guérin therapy: A Japan Urological Oncology Group study analysis.
Nishikawa R, Miyake M, Morizane S, Shimizu R, Teraoka S, Honda M, Iida K, Nishimura N, Sazuka T, Kimura T, Ito A, Shiga K, Taoka R, Kojima T, Kobayashi T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K, Takenaka A. Nishikawa R, et al. Among authors: nishiyama h, nishiyama n. Int J Urol. 2023 Mar;30(3):299-307. doi: 10.1111/iju.15106. Epub 2022 Nov 30. Int J Urol. 2023. PMID: 36448522
Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi‑institutional retrospective study.
Kato R, Naito S, Numakura K, Hatakeyama S, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N, Obara W. Kato R, et al. Among authors: nishiyama h. Int J Clin Oncol. 2023 May;28(5):726-727. doi: 10.1007/s10147-023-02331-z. Int J Clin Oncol. 2023. PMID: 37010622 Free PMC article. No abstract available.
Subsequent Upper Urinary Tract Carcinoma Related to Worse Survival in Patients Treated with BCG.
Numakura K, Miyake M, Kobayashi M, Muto Y, Sekine Y, Nishimura N, Iida K, Shiga M, Morizane S, Yoneyama T, Matsumura Y, Abe T, Yamada T, Matsumoto K, Inokuchi J, Nishiyama N, Taoka R, Kobayashi T, Kojima T, Kitamura H, Nishiyama H, Fujimoto K, Habuchi T. Numakura K, et al. Among authors: nishiyama h, nishiyama n. Cancers (Basel). 2023 Mar 28;15(7):2002. doi: 10.3390/cancers15072002. Cancers (Basel). 2023. PMID: 37046663 Free PMC article.
Sexual function using the EORTC QLQ-TC26 in testicular cancer survivors: A multi-institutional, cross-sectional study.
Koyama J, Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Nishimura K, Nonomura N, Nishiyama H, Shiraishi T, Ukimura O, Ogawa O, Shinohara N, Suzukamo Y, Ito A, Arai Y. Koyama J, et al. Among authors: nishiyama h. Int J Urol. 2023 Nov;30(11):1044-1050. doi: 10.1111/iju.15262. Epub 2023 Jul 31. Int J Urol. 2023. PMID: 37522577
Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Nishiyama H, Inoue T, Koizumi Y, Kobayashi Y, Kitamura H, Yamamoto K, Takeda T, Yamamoto T, Yamamoto R, Matsubara T, Hoshino J, Yanagita M; committee of Clinical practice guidelines for the management of kidney disease during anticancer drug therapy 2022. Nishiyama H, et al. Int J Clin Oncol. 2023 Oct;28(10):1298-1314. doi: 10.1007/s10147-023-02377-z. Epub 2023 Aug 12. Int J Clin Oncol. 2023. PMID: 37572198 Review.
Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group.
Horie S, Naito S, Hatakeyama S, Kandori S, Numakura K, Kato R, Koguchi T, Myoen S, Kawasaki Y, Ito A, Adachi H, Kojima Y, Obara W, Habuchi T, Nishiyama H, Ohyama C, Tsuchiya N. Horie S, et al. Among authors: nishiyama h. Int J Clin Oncol. 2023 Nov;28(11):1538-1544. doi: 10.1007/s10147-023-02401-2. Epub 2023 Sep 22. Int J Clin Oncol. 2023. PMID: 37740070
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.
Minami K, Osawa T, Kojima T, Hara T, Eto M, Takeuchi A, Nakai Y, Ueda K, Ozawa M, Uemura M, Ohba K, Tamura K, Shindo T, Nakagomi H, Takahashi A, Anai S, Yokomizo A, Morizane S, Kimura T, Shimazui T, Miyauchi Y, Mitsuzuka K, Hara H, Yoshimura K, Shiina H, Ito YM, Murai S, Nishiyama H, Shinohara N, Kitamura H; Japanese Urological Oncology Group. Minami K, et al. Among authors: nishiyama h. Urol Oncol. 2023 Nov;41(11):458.e9-458.e19. doi: 10.1016/j.urolonc.2023.08.008. Epub 2023 Oct 3. Urol Oncol. 2023. PMID: 37798145
Comparison of perioperative outcomes and complications between intracorporeal, extracorporeal, and hybrid ileal conduit urinary diversion during robot-assisted radical cystectomy: a comparative propensity score-matched analysis from nationwide multi-institutional study in Japan.
Morizane S, Nakane K, Tanaka T, Zennami K, Muraoka K, Ebara S, Miura N, Uemura K, Sobu R, Hoshi A, Taoka R, Sugimoto M, Noma H, Sunada H, Nishiyama H, Habuchi T, Ikeda I, Saika T, Makiyama K, Shiroki R, Masumori N, Koie T, Takenaka A. Morizane S, et al. Among authors: nishiyama h. Int J Clin Oncol. 2024 Jan;29(1):64-71. doi: 10.1007/s10147-023-02425-8. Epub 2023 Oct 21. Int J Clin Oncol. 2024. PMID: 37864612
1,092 results